Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma

• Published in: Pulmonary pharmacology & therapeutics Vol. 29; no. 1; pp. 15 - 23
• Main Authors: Barchuk, W, Lambert, J, Fuhr, R, Jiang, J.Z, Bertelsen, K, Fourie, A, Liu, X, Silkoff, P.E, Barnathan, E.S, Thurmond, R
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2014
• Subjects: Acetates - pharmacology; Adult; Anti-Asthmatic Agents - adverse effects; Anti-Asthmatic Agents - pharmacology; Asthma; Asthma - drug therapy; Asthma - physiopathology; Bronchial Provocation Tests; Cross-Over Studies; Double-Blind Method; Epoxide Hydrolases - antagonists & inhibitors; Female; Forced Expiratory Volume; Humans; Hypersensitivity; Leukotriene antagonist; Leukotriene B4 - metabolism; Leukotriene synthesis inhibitor; Male; Medical Education; Montelukast; Pulmonary/Respiratory; Quinolines - pharmacology; Sputum - metabolism; Thiazoles - adverse effects; Thiazoles - pharmacology; Treatment Outcome; Tropanes - adverse effects; Tropanes - pharmacology; Young Adult; Montelukast; Leukotriene antagonist; Leukotriene synthesis inhibitor; Hypersensitivity; Asthma

Abstract Leukotriene B4 (LTB4 ) is a chemotactic mediator implicated in the pathogenesis of asthma. JNJ-40929837 is an oral inhibitor of LTA4 hydrolase, which catalyzes LTB4 production. We evaluated the effects of JNJ-40929837 in a human bronchial allergen challenge (BAC) model. In this double-blind...